The ESC Textbook of Thrombosis

Description:

The ESC Textbook of Thrombosis is the third iteration of Therapeutic Advances in Thrombosis. Now a new addition to the European Society of Cardiology (ESC) publications portfolio, it is informed by the work of the ESC's Working Group on Thrombosis.
Written by internationally renowned experts in the field of thrombosis, the textbook presents an up-to-date and in-depth review of all aspects of thrombosis and antithrombotic therapies. Not only does it reflect contemporary European guidelines from the ESC but also it also summarizes the latest evidence from clinical trials.
Covering the topic in great detail with thirty-one chapters, the textbook is split into four sections: Pathophysiology of thrombosis, Clinical pharmacology of antithrombotic drugs, Therapeutic strategies, and Special situations.
Appealing to the large community of cardiovascular healthcare specialists in Europe and across the world, the textbook is a must read for cardiologists dealing with acute and chronic coronary syndromes, atrial fibrillation, artificial heart valves and pulmonary embolism. It will also appeal to cardiac surgeons, cardiovascular researchers, and general physicians alike.

Table of Contents:

1:Introduction, Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen
Section 1: Pathophysiology of thrombosis
2:Arterial thrombosis: Pathophysiological background, Lina Badimon and Gemma Vilahur
3:Venous thrombosis and thromboembolism: Pathophysiological background, Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es
4:Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background, Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip
5:Thrombosis on foreign surfaces and devices, Tobias Geisler
Section 2: Clinical pharmacology of antithrombotic drugs
6:Aspirin, Carlo Patrono and Bianca Rocca
7:Platelet P2Y12 inhibitors, Manan Pareek and Deepak L. Bhatt
8:Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists, Luis Ortega-Paz and Dominick Angiolillo
9:Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid, Renske Olie and Hugo ten Cate
10:Vitamin K antagonists, Freek W.A. Verheugt and Marc Brouwer
11:Dabigatran, Alex Benz and Stefan Hohnloser
12:Oral factor Xa (FXa) inhibitors, Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen
13:Forthcoming oral factor XIa and FXIIa inhibitors, James C. Fredenburgh and Jeffrey I. Weitz
14:Thrombolytic therapy and ancillary antithrombotic therapies, Peter R Sinnaeve and Frans Van de Werf
Section 3: Therapeutic strategies
15:Antithrombotic strategies in primary cardiovascular prevention, Raffaele De Caterina, Paul M Ridker, and Erica Michelotti
16:Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions, Antonio Greco and Davide Capodanno
17:Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes, William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey
18:Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions, Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno
19:Antithrombotic therapies in ischaemic stroke, Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom
20:Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis, Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove
21:Atrial fibrillation: current and forthcoming antithrombotic therapies, Raffaele De Caterina and Rossella Marcucci
22:Venous thromboembolism: prophylaxis and treatment, Chaozer Er, Walter Ageno, and Ander Cohen
23:Biomarker-based risk stratification in cardiovascular disease, Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck
Section 4: Special situations
24:Antithrombotic therapies in inherited or acquired thrombophilia, Vittorio Pengo and Gentian Denas
25:Prevention and treatment of bleeding related to antithrombotic drug treatment, Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao
26:Management of patients treated with antithrombotic drugs undergoing surgery, Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula
27:Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome, Alexander C Fanaroff, Renato D Lopes, John H Alexander
28:Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy, Stefan Agewall, Vanessa Roldán, and Francisco Marín
29:Antithrombotic agents and drug-drug interactions, Steven P. Dunn, Craig J. Beavers, and David J. Moliterno
30:Personalised antithrombotic therapy: Measuring individual variation and monitoring, Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas
31:Drug development, clinical trials, and regulatory requirements, Serge Korjian, Yazan Daaboul, and C. Michael Gibson